New hope for sickle cell cure: gentler transplant trial opens for patients with organ damage
NCT ID NCT06145282
Summary
This study is testing a new combination of drugs designed to make a curative stem cell transplant safer, especially for sickle cell patients who already have damage to organs like their heart, lungs, or kidneys. The goal is to help the patient's body accept donor cells without severe side effects. Participants are adults and teens (16+) with severe sickle cell disease who have a partially matched family donor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.